Details for Patent: 7,662,818
✉ Email this page to a colleague
Title: | Phthalazinone derivatives |
Abstract: | Compounds of the formula (I): ##STR00001## wherein A and B together represent an optionally substituted, fused aromatic ring; X can be NR.sup.X or CR.sup.XR.sup.Y; if X=NR.sup.X then n is 1 or 2 and if X=CR.sup.XR.sup.Y then n is 1; R.sup.X is selected from the group consisting of H, optionally substituted C.sub.1-20 alkyl, C.sub.5-20 aryl, C.sub.3-20 heterocyclyl, amido, thioamido, ester, acyl, and sulfonyl groups; R.sup.Y is selected from H, hydroxy, amino; or R.sup.X and R.sup.Y may together form a spiro-C.sub.3-7 cycloalkyl or heterocyclyl group; R.sup.C1 and R.sup.C2 are both hydrogen, or when X is CR.sup.XR.sup.Y, R.sup.C1, R.sup.C2, R.sup.X and R.sup.Y, together with the carbon atoms to which they are attached, may form an optionally substituted fused aromatic ring; and R.sup.1 is selected from H and halo. |
Inventor(s): | Martin; Niall Morrison Barr (Cambridge, GB), Smith; Graeme Cameron (Cambridge, GB), Jackson; Stephen Philip (Cambridge, GB), Loh; Vincent Junior M (Horsham, GB), Cockcroft; Xiao-Ling Fan (Horsham, GB), Matthews; Ian Timothy Williams (Horsham, GB), Menear; Keith Allan (Horsham, GB), Kerrigan; Frank (Cornwall, GB), Ashworth; Alan (London, GB) |
Assignee: | Kudos Pharmaceuticals Limited (Cambridge, GB) Maybridge Limited (Cornwall, GB) |
Filing Date: | Dec 23, 2005 |
Application Number: | 11/318,155 |
Claims: | 1. A compound of the formula (I): ##STR00446## or an isomer thereof, or a salt thereof, wherein: A and B together represent an optionally substituted, fused aromatic ring; X is CR.sup.XR.sup.Y; n is 1; R.sup.X is selected from hydrogen, optionally substituted C.sub.1-20 alkyl, optionally substituted C.sub.5-20 aryl, optionally substituted C.sub.3-20 heterocyclyl, optionally substituted amido, optionally substituted thioamido, optionally substituted ester, optionally substituted acyl, and optionally substituted sulfonyl groups; R.sup.Y is selected from hydrogen, hydroxy, and amino; or R.sup.X and R.sup.Y may together form a spiro-C.sub.3-7 cycloalkyl or heterocyclyl group; R.sup.C1 and R.sup.C2 are both hydrogen, or R.sup.C1, R.sup.C2, R.sup.X and R.sup.Y together with the carbon atoms to which they are attached, may form an optionally substituted fused aromatic ring; and R.sup.1 is selected from hydrogen and halo. 2. A compound according to claim 1, wherein the fused aromatic ring(s) represented by -A-B-- consist of solely carbon ring atoms. 3. A compound according to claim 2, wherein the fused aromatic ring represented by -A-B-- is benzene. 4. A compound according to claim 1, wherein R.sup.1 is selected from hydrogen, Cl and F. 5. A compound according to claim 1, wherein R.sup.C1 and R.sup.C2 are both hydrogen. 6. A compound according to claim 1, wherein R.sup.Y is hydrogen, and R.sup.X is selected from hydrogen; optionally substituted C.sub.1-20 alkyl; optionally substituted C.sub.5-20 aryl; optionally substituted C.sub.3-20 heterocyclyl; optionally substituted acyl; optionally substituted amido; and optionally substituted ester groups. 7. A pharmaceutical composition comprising a compound according to claim 1 and one or more pharmaceutically acceptable carriers, excipients, buffers, adjuvants, or stabilisers. |